George Flores

Fredonia Mining advances its flagship gold project while consolidating a key Argentine district, a bold strategy to build a regional powerhouse next to giants.

Nasdaq is launching a research institute, but the real story is its first report: a surge of solo entrepreneurs, armed with AI, is redrawing the economic map.

With a new CFO skilled in scaling hardtech and a new deal-making chief, Fortera is signaling its move from the lab to the global market.

Hyderabad's Trex Energy launches its liquid-cooled REX BESS, a strategic play timed perfectly with new policies mandating energy storage in India.

Insulet unveils new data for its Omnipod 6 and a fully closed-loop system, signaling a major strategic push into the vast, untapped type 2 diabetes market.

Sleep is now a bankable asset. A new wave of research is changing how high-stakes industries like aviation manage fatigue, turning rest into a strategic advantage.

The new WeTrade-Rockets deal targets global fans, but a closer look reveals a complex web of regulations and high-risk products behind the glossy campaign.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

As Better Blend enters Tampa, its model reveals a new fast-casual paradigm where operational speed and personalized health aren't just perks—they're the core product.

As the deadly Bundibugyo Ebola strain spreads with no approved vaccine, a small pharma company is positioning its cancer drug as a potential broad-spectrum shield.

Cynapse.ai's new cyRoad platform promises to turn existing traffic cameras into a proactive intelligence network, saving money and lives without costly overhauls.

A new partnership with Scala.AI aims to move beyond simple telehealth, using deep operational intelligence to fix healthcare's costly fragmentation and poor navigation.

The Hawaiian coffee brand is bypassing real estate hurdles with a mix of cafes and kiosks to conquer the crowded Southeast. Here's the strategic calculus.

Zepto Life Technology's FDA Breakthrough status for a fungal test isn't just a win for patients; it's a strategic move in liquid biopsy's new frontier.

MetTel's recent Gartner recognition is more than an accolade; it's a signpost for the future of work where AI and automation manage our corporate devices.

Epson challenges display giants with its first dvLED line, leveraging advanced COB tech and a simplified design in a bold move beyond its projector legacy.

As demand for solar surges, a new report reveals alarming failure rates in PV modules, forcing a high-stakes reckoning over long-term performance and profit.

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

Petco Love's massive adoption event is more than a feel-good story; it's a calculated response to an economic crisis forcing New Yorkers to surrender pets.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.